Research programme: small molecule cardiovascular therapeutics - Gilead Sciences

Drug Profile

Research programme: small molecule cardiovascular therapeutics - Gilead Sciences

Latest Information Update: 14 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences; University of Texas Southwestern Medical Center
  • Developer Gilead Sciences; Novartis; University of Texas Southwestern Medical Center
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 14 Jul 2010 Discontinued - Preclinical for Heart failure in USA (unspecified route)
  • 18 Nov 2006 Myogen has been acquired by Gilead Sciences
  • 13 Jul 2006 Myogen and Novartis have extended their licensing agreement through October 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top